Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on February 3, 2021, covering events occurring on February 1 and February 2, 2021. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Austin, Texas.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Departure of CFO: Charles N. York, who served as Chief Financial Officer, Vice President, and Secretary, notified the Company of his resignation, effective February 12, 2021.
- Appointment of Principal Accounting Officer: On February 2, 2021, the Company appointed Steven Weber, Vice President and Corporate Controller, as its principal accounting officer, effective immediately.
Management Commentary and Risks
Mr. Weber brings over 20 years of finance experience, having served as the Company's Vice President and Corporate Controller since January 2021 and in prior controller roles since 2014. He is a CPA in Texas and previously worked at PricewaterhouseCoopers LLP. The Company entered into a standard indemnification agreement with Mr. Weber. The filing states there are no undisclosed arrangements regarding his appointment, no family relationships with directors or officers, and no material interests in transactions requiring disclosure.
Investor Verification Checklist
- Verify the transition timeline for the CFO role between Charles N. York's departure on February 12, 2021, and any potential permanent replacement.
- Confirm the status of the Company's financial reporting and internal controls during the interim period following the CFO's resignation.
- Review the standard indemnification agreement referenced in the filing (Exhibit 10.1 to the 2018 10-K) for specific terms applicable to Mr. Weber.